|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/15/22 PERRIGO Co. plc 8-K/A:2,9 4/29/22 14:1.4M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size 1: 8-K/A Amendment to Current Report HTML 38K 2: EX-23.1 Consent of Expert or Counsel HTML 7K 3: EX-99.1 Miscellaneous Exhibit HTML 687K 4: EX-99.2 Miscellaneous Exhibit HTML 430K 9: R1 Document and Entity Information HTML 67K 12: XML IDEA XML File -- Filing Summary XML 13K 10: XML XBRL Instance -- d374236d8ka_htm XML 32K 11: EXCEL IDEA Workbook of Financial Reports XLSX 9K 6: EX-101.DEF XBRL Definitions -- prgo-20220429_def XML 48K 7: EX-101.LAB XBRL Labels -- prgo-20220429_lab XML 80K 8: EX-101.PRE XBRL Presentations -- prgo-20220429_pre XML 50K 5: EX-101.SCH XBRL Schema -- prgo-20220429 XSD 19K 13: JSON XBRL Instance as JSON Data -- MetaLinks 16± 24K 14: ZIP XBRL Zipped Folder -- 0001193125-22-194099-xbrl Zip 125K
| 8-K/A |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
Perrigo Company plc
(Exact name of registrant as specified in its charter)
| Commission file number i 001-36353 | ||||
| i Ireland | Not Applicable | |||
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
i The Sharp Building, i Hogan Place, i Dublin 2, i Ireland i D02 TY74
+ i 353 1 i 7094000
(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities Registered pursuant to section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| i Ordinary shares, €0.001 par value | i PRGO | i New York Stock Exchange | ||
| i 4.000% Notes due 2023 | i PRGO23 | i New York Stock Exchange | ||
| i 3.900% Notes due 2024 | i PRGO24 | i New York Stock Exchange | ||
| i 4.375% Notes due 2026 | i PRGO26 | i New York Stock Exchange | ||
| i 3.15% Notes due 2030 | i PRGO30 | i New York Stock Exchange | ||
| i 5.300% Notes due 2043 | i PRGO43 | i New York Stock Exchange | ||
| i 4.900% Notes due 2044 | i PRGO44 | i New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.01 | Completion of Acquisition or Disposition of Assets. |
As previously reported, on April 29, 2022, Perrigo Company plc (the “Company”) completed the acquisition of Héra SAS (“HRA Pharma”).
i This Amendment No. 1 to Current Report on Form 8-K/A (“Amendment No. 1”) is filed to amend the Current Report on Form 8-K filed with the Securities and Exchange Commission by the Company on May 2, 2022 to include the historical financial statements of HRA Pharma and certain pro forma financial information required by Item 9.01 (a) and (b) of Form 8-K.
The pro forma financial information included in this Amendment No. 1 has been presented for informational purposes only. It does not purport to represent the actual results of operations that the Company and HRA Pharma would have achieved had the companies been combined during the periods presented in the pro forma financial information and is not intended to project the future results of operations that the combined company may achieve after the consummation of the acquisition.
| Item 9.01 | Financial Statements and Exhibits. |
(a) Financial Statements of Businesses Acquired
The audited consolidated financial statements of Héra SAS as of and for the year ended December 31, 2021 are included as Exhibit 99.1 to this Current Report on Form 8-K/A.
(b) Pro Forma Financial Information
The unaudited pro forma condensed combined financial information as of and for the year ended December 31, 2021 is included as Exhibit 99.2 to this Current Report on Form 8-K/A.
(d) Exhibits
| Exhibit Number |
Description | |
| 23.1 | Consent of KPMG S.A., independent auditors of Héra SAS. | |
| 99.1 | Audited consolidated financial statements of Héra SAS as of and for the year ended December 31, 2021. | |
| 99.2 | Unaudited pro forma condensed combined financial information of the Company after giving effect to the acquisition as of and for the year ended December 31, 2021. | |
| 104 | Cover Page Interactive Data file (embedded within the Inline XBRL document). | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| (Registrant) | ||||||
| PERRIGO COMPANY PLC | ||||||
| By: | /s/ Eduardo Bezerra | |||||
| Dated: July 15, 2022 | Eduardo Bezerra | |||||
| Chief Financial Officer | ||||||
| This ‘8-K/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 7/15/22 | |||
| 5/2/22 | 8-K | |||
| For Period end: | 4/29/22 | 8-K | ||
| 12/31/21 | 10-K, 11-K, 5 | |||
| List all Filings | ||||